SARS-CoV-2 emerged in 2019 and led to the COVID-19 pandemic. Efforts to develop therapeutics against SARS-Cov-2 led to both new treatments and attempts to repurpose existing medications. Here, we provide a narrative review of the xenobiotics and alternative remedies used or proposed to treat COVID-19. Most repositioned xenobiotics have had neither the feared toxicity nor the anticipated efficacy. Repurposed viral replication inhibitors are not efficacious and frequently associated with nausea, vomiting, and diarrhea. Antiviral medications designed specifically against SARS-CoV-2 may prevent progression to severe disease in at-risk individuals and appear to have a wide therapeutic index. Colloidal silver, zinc, and ivermectin have no demonstrated efficacy. Ivermectin has a wide therapeutic index but is not efficacious and acquiring it from veterinary sources poses additional danger. Chloroquine has a narrow therapeutic index and no efficacy. A companion review covers vaccines, monoclonal antibodies, and immunotherapies. Together, these two reviews form an update to our 2020 review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756926 | PMC |
| http://dx.doi.org/10.1007/s13181-022-00918-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic variation reveals the therapeutic potential of BRSK2 in idiopathic pulmonary fibrosis.
BMC Med
January 2025
Department of Cardiothoracic Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Background: Current research underscores the need to better understand the pathogenic mechanisms and treatment strategies for idiopathic pulmonary fibrosis (IPF). This study aimed to identify key targets involved in the progression of IPF.
Methods: We employed Mendelian randomization (MR) with three genome-wide association studies and four quantitative trait loci datasets to identify key driver genes for IPF.
Double-Negative CD4 CD8 Absolute Count Plays a Mediating Role in the Causal Relationship Between Plasma Lipids and Parkinson's Disease: A Mendel Randomized Study.
Mol Neurobiol
January 2025
Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Xuhui District, No. 725 South Wan-Ping Road, Shanghai, 200032, China.
According to certain research, there might be a connection between Parkinson's disease and plasma lipidome. However, the causal effects between plasma lipidome and Parkinson's disease and whether immune cells act as a mediator remain unclear. According to some research, plasma lipids are an important risk factor for Parkinson's disease, however, whether there is a causative connection between the two is unclear.
View Article and Find Full Text PDFA novel approach for managing the incisions of tibial plateau fractures with soft tissue swelling.
Sci Rep
January 2025
Department of Orthopaedics, The Second Hospital, Cheeloo College of Medicine, Shandong University, 247 Beiyuan Street, Jinan, 250033, Shandong, People's Republic of China.
To investigate the feasibility and clinical efficacy of a novel approach to managing the incisions used to treat tibial plateau fractures (TPFs) with soft tissue swelling. We retrospectively enrolled 64 patients with TPFs who underwent surgery at the Second Hospital of Shandong University. Patients were divided into two groups: Group A (n = 32) underwent early surgery with the novel incision management technique, and Group B (n = 32) underwent conventional surgery after swelling reduction.
View Article and Find Full Text PDFTissue degrading and remodelling molecules in giant cell arteritis.
Rheumatology (Oxford)
January 2025
Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Objectives: GCA is a granulomatous vasculitis affecting large vessels, leading to intimal occlusion accompanied by the accumulation of myofibroblasts. Histopathologically, GCA is characterized by destruction of the tunica media and hypertrophy of the intima with invasion of activated CD4+ T cells, macrophages and multinucleated giant cells (MNGCs). Despite these well-defined histopathological features, the molecular pathology of GCA has largely remained elusive.
View Article and Find Full Text PDFInhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.
PLoS One
January 2025
Department of Basic Sciences, Bioethics and Human Life, Faculty of Human Medicine, University of Piura, Miraflores, Lima, Perú.
The anaplastic lymphoma kinase (ALK) oncoprotein plays a crucial role in non-small cell lung cancer (NSCLC) by activating signaling pathways involved in cell proliferation and survival through constitutive phosphorylation. While first-line crizotinib can regulate phosphorylation, mutations in the ALK gene can lead to resistance against ALK inhibitors (ALKi) such as ceritinib and alectinib. On the other hand, overexpression of BCL2, a protein involved in cell death regulation, has been observed in NSCLC and is considered a potential therapeutic target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!